Efficacy and safety of sofosbuvir-based therapy for aged patients with chronic hepatitis C
AASLD LiverLearning®, Ayako Urabe, 144897
Virological Response rates using Generic Direct Acting Antiviral Treatment for Hepatitis C, Legally Imported into Russia
AASLD LiverLearning®, Julia Dragunova, 144913
Predictors of mortality in patients hospitalized with spontaneous bacterial peritonitis: Analysis of National Inpatient Sample, 2009-2011
AASLD LiverLearning®, Bryan Love, 144929
Protective effects of beta-blockers in patients with acute-on-chronic liver failure including circulatory failure requiring vasopressors
AASLD LiverLearning®, Mohammed Yaquob, 144945
AKI In Critically Ill Cirrhotics With Severe Sepsis And Septic Shock Has Major Influence On Organ Failures And Outcomes- A Prospective Study
AASLD LiverLearning®, RAKHI MAIWALL, 144961
Bacterascites is associated with poor clinical outcome in decompensated cirrhosis.
AASLD LiverLearning®, Rosalie C. Oey, 144977
Pulse Shaping for Improved Diagnosis of Portal Hypertension Using Subharmonic Aided Pressure Estimation
AASLD LiverLearning®, Ipshita Gupta, 144993
High efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 12 weeks in treatment of genotype 1b HCV infected cirrhotic patients: a large real world cohort
AASLD LiverLearning®, Irina Girleanu, 144881
Module 1: Anatomy and Physiology of the Liver
AASLD LiverLearning®, Tamar Taddei, 119131
Management of Hepatic Encephalopathy
AASLD LiverLearning®, Jasmohan Bajaj, 154717
Surgery Risk Assessment in the Cirrhotic Patient
AASLD LiverLearning®, Patrick Northup, 154716
Update in Wilson Disease
AASLD LiverLearning®, Eve Roberts, 154715
Pegylated interferon alfa-2a (40KD) is efficacious and safe in treatment of HBeAg-positive children with chronic hepatitis B: Peg-B-Active study
AASLD LiverLearning®, Stefan Wirth, 155355
Hepatology Associates Course
AASLD LiverLearning®, Session Speakers, 155769
HIV, HBV, HCV Coinfections
AASLD LiverLearning®, Douglas Dieterich, 154676
Approach to the Patient with Iron Overload
AASLD LiverLearning®, Kris Kowdley, 154675
Adult Living Donor Liver Transplant: Donor and Recipient Considerations
AASLD LiverLearning®, Rebecca Duke, 154674
Awarded Poster Presentation
AASLD LiverLearning®, Anna Hefner, 154673
iPSC and Disease Modeling in the Liver
AASLD LiverLearning®, Ludovic Vallier, 154691
The Impact of Cirrhotic PVT on Liver Transplant: A Medical Perspective
AASLD LiverLearning®, Nicolas Intagliata, 154701
Complications of Cholestatic Liver Diseases
AASLD LiverLearning®, Cynthia Levy, 154672
iPSCs and Correction of A1AT Deficiency
AASLD LiverLearning®, Andrew Wilson, 154690
Cholangiocytes From iPSC
AASLD LiverLearning®, Romina Fiorotto, 155708
Treatment of PVT in Cirrhosis: Who, When and How
AASLD LiverLearning®, Juan Carlos Garcia-Pagan, 154700
Etiology of Liver Disease: Does it Make a Clinical Difference?
AASLD LiverLearning®, Jordi Bruix, 154712
Hepatocytes From iPSC
AASLD LiverLearning®, Holger Willenbring, 154688
Diagnosis and Natural History of PVT In Cirrhosis
AASLD LiverLearning®, Dominique Valla, 154699
Statins and Metformin as Chemoprevention for HCC
AASLD LiverLearning®, Lewis Roberts, 154711
Panel Discussion
AASLD LiverLearning®, Session Speakers, 155768
Future Landscape With HCV Therapy
AASLD LiverLearning®, Fred Poordad, 154669
Session II: Epidemiology and Clinical Insights
AASLD LiverLearning®, Gregory Gores, 154709
Liver Transplantation for NASH Associated HCC
AASLD LiverLearning®, Kimberly Ann Brown, 154710
Cirrhosis – Beyond Portal Hypertension
AASLD LiverLearning®, Lucy Mathew, 154668
Engineering of the Liver via iPSC
AASLD LiverLearning®, Takanori Takebe, 154685
Does Prophylactic Anticoagulation Alter the Course of Cirrhosis? Lessons from Prophylactic Trials
AASLD LiverLearning®, ERICA VILLA, 154698
Natural History: The Magnitude of the Problem from Hepatology Clinic Perspective
AASLD LiverLearning®, Augusto Villanueva, 154708
Parenchymal Extinction in 2016: What is the Human Evidence?
AASLD LiverLearning®, Ian R. Wanless, 154697
Management of Metabolic Syndrome and NASH
AASLD LiverLearning®, Rohit Loomba, 154667
Induced Pluripotent Stem Cells in the Future of Gastroenterology/Hepatology
AASLD LiverLearning®, Stephen Duncan, 154684
Diabetes Associated HCC: The Molecular Profile
AASLD LiverLearning®, Jessica Zucman-Rossi, 154707
Coagulation, Thrombin, Fibrosis and Inflammatory Pathways in the Liver
AASLD LiverLearning®, James Luyendyk, 154696
NAFLD Promotes HCC by Causing CD4(+)T Cell Depletion
AASLD LiverLearning®, Tim Greten, 154706
Developmental Biology: The Foundation for Gastrointestinal Tissue Engineering
AASLD LiverLearning®, James Wells, 154681
Hepatology Associates Course: Session I
AASLD LiverLearning®, Lisa Richards, 154664
Managing Alcoholic Hepatitis
AASLD LiverLearning®, Vijay Shah, 154666
Cirrhosis as a Prothrombotic State: Overview and Update
AASLD LiverLearning®, Ton Lisman, 154695
ALBI and PALBI Grade Predict Survival for HCC across Treatment Modalities and BCLC Stages in the MELD Era
AASLD LiverLearning®, Po-Hong Liu, 144141
Year 2 serum HBV DNA detectability predicts hepatocellular carcinoma in entecavir-treated patients - a 7-year cohort study of 1,680 patients with chronic hepatitis B
AASLD LiverLearning®, Grace Wong, 144142
The Dual Glucagon-Like Peptide-1 (GLP-1)/Glucagon Receptor Agonist MEDI0382 Improves Metabolic and Hepatic Indices of NASH in Mice
AASLD LiverLearning®, James Trevaskis, 144398
Group 2 Innate Lymphoid Cells (ILC2s) are Altered in Fatty Liver Disease
AASLD LiverLearning®, Lucy Golden-Mason, 144399
Early decrease in alfafetoprotein as a prognosis factor of response in patients with advanced hepatocellular carcinoma treated with sorafenib
AASLD LiverLearning®, Teresa Ferrer Rios, 144157
Non-alcoholic fatty liver disease (NAFLD) is associated with low surveillance rate and advanced hepatocellular carcinoma (HCC) at diagnosis
AASLD LiverLearning®, Yi Huang, 144158
The dual FXR/TGR5 agonist INT-767 inhibits nonalcoholic steatohepatitis development in a rabbit model of metabolic syndrome
AASLD LiverLearning®, Luciano Adorini, 144414
iPLA2beta deficiency attenuates obesity and steatosis in long-term HFD fed mice through an alteration of hepatic phospholipids
AASLD LiverLearning®, Ann-Christin Otto, 144415
Vitamin K supplementation decreased the incidence of severe hand-foot skin reaction during sorafenib treatment for hepatocellular carcinoma.
AASLD LiverLearning®, Yoshimichi Haruna, 144173
Risk factors for liver cancer in chronic hepatitis C are different between the early and late periods after sustained virological response.
AASLD LiverLearning®, RYOKO YAMADA, 144174
L-Selectin (CD62L) drives development and progression of non-alcoholic steatohepatitis (NASH) in two dietary mouse models
AASLD LiverLearning®, Hannah Drescher, 144430
L-carnitine attenuates oxidative stress and inflammatory reactions in steatohepatitis in diabetic KK-Ay mice
AASLD LiverLearning®, Kazuyoshi Kon, 144431
Role of Aberrant NDRG3 Expression in Human Hepatocellular Carcinoma
AASLD LiverLearning®, Jin Jeong, 144189
Barcelona Clinic Liver Cancer (BCLC) Versus Hong Kong Liver Cancer (HKLC) Staging Systems in an Asian Tertiary Centre - A review of 1270 patients from a multiracial Asian population
AASLD LiverLearning®, Weiquan James Li, 144190
Crystalized cholesterol leads to inflammasome activation and marks the transition from simple steatosis to steatohepatitis in humans with NASH and in mice with high-fat diet-induced steatohepatitis.
AASLD LiverLearning®, Angela Dolganiuc, 144446
Activating Transcription Factor 3 Is a Targeted Molecule Linking Hepatic Steatosis To Type 2 Diabetes
AASLD LiverLearning®, Won Kim, 144447
A Novel Single Daily Fixed Dose Combination of Sofosbuvir400 mg + Ribavirin1000mg + EGCG400 mg is Superior to the Standard of Care as an Anti-Viral and Safer Causing less Hemolysis in Patients with Chronic Hepatitis C
AASLD LiverLearning®, Gamal Shiha, 154955
Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort
AASLD LiverLearning®, Neehar Parikh, 144205
Treatment-integrated Nomogram of the Barcelona Clinic Liver Cancer System for Patients with Hepatocellular Carcinoma
AASLD LiverLearning®, Chia-Yang Hsu, 144206
EP-024297, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits High Potency and Efficacy In Vitro and In Vivo
AASLD LiverLearning®, Lijuan Jiang, 144462
Sphingosine 1-Phosphate (S1P)/S1P Receptor 2/3 Mediates M1 Type Polarization of Bone Marrow-Derived Monocytes/Macrophages in Non-alcoholic Steatohepatitis
AASLD LiverLearning®, Liying Li, 144463
Spexin, a novel regulator of lipid & carbohydrate metabolism, is a potential therapeutic for obesity, type 2 diabetes mellitus, & non-alcoholic fatty liver disease.
AASLD LiverLearning®, Paul Berk, 154971
Surveillance for Hepatobiliary Cancer in Primary Sclerosing Cholangitis
AASLD LiverLearning®, Navine Nasser-Ghodsi, 144221
Mortality and morbidity with endoscopic versus percutaneous biliary drainage in palliation of unresectable hilar cholangiocarcinoma: A meta-analysis and systematic review.
AASLD LiverLearning®, Abhiram Duvvuri, 144222
Aroclor 1260 disrupts the hepatic proteome in the development of NASH
AASLD LiverLearning®, Josiah Hardesty, 144479
Is percutaneous approach better than endoscopic approach for successful biliary drainage in palliation of unresectable hilar cholangiocarcinoma: A meta-analysis and systematic review.
AASLD LiverLearning®, Abhiram Duvvuri, 144237
Validation of tumor factor of staging systems in hepatocellular carcinoma; focusing on the difference between each staging system
AASLD LiverLearning®, Sadahisa Ogasawara, 144238
Metabolomic classification of murine and human nonalcoholic fatty liver disease
AASLD LiverLearning®, Cristina Alonso, 144495
Poor Glycemic Control in Patients with Diabetes Increases the Risk of Hepatocellular Carcinoma
AASLD LiverLearning®, Jeffrey Nadelson, 144253
Risk of Hepatocellular Carcinoma after Antiviral Therapy in Different Sets of Korean Patients with Chronic Hepatitis C
AASLD LiverLearning®, Sangyoung Yi, 144254
The hypoxia-mimetic agent CoCl2 induces proinflammatory and profibrotic signals as well as inflammasome activation in liver cells
AASLD LiverLearning®, Alejandra Hernández, 144512
Factors Associated with Misdiagnosis of Hepatocellular Carcinoma before Liver Transplant with No Tumors Found on Explant: An Analysis of the UNOS database
AASLD LiverLearning®, Neil Mehta, 144269
Significant of Hepatectomy for Stage B and C Hepatocellular Carcinoma in the BCLC Classification
AASLD LiverLearning®, Toshiya Kamiyama, 144270
Treatment of Hepatitis C with ledipasvir, sofosbuvir with or without ribavirin in post liver transplant patients in an academic center.
AASLD LiverLearning®, Merlin Punnoose, 144528
Hepatic venous outflow obstruction in polycystic liver disease: impact on pathology and intra and postoperative course after liver resection
AASLD LiverLearning®, Louise Barbier, 144285
Impact of Acute-On-Chronic Liver Failure on 90-day Mortality following Liver Transplantation
AASLD LiverLearning®, Cyrille Feray, 144286
Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure (ACLF) with Hepatic Encephalopathy (HE): A Randomized Trial (ClinicalTrials.gov Identifier: NCT02321371)
AASLD LiverLearning®, Anand Kulkarni, 144301
Bone Forming cells are Decreased in Osteopenic and Osteoporostic Conditions in Cirrhosis Patients.
AASLD LiverLearning®, Chhagan Bihari, 144302
Early impaired neurological functioning after TIPS placement: a multimodal MRI studies
AASLD LiverLearning®, Marika Rudler, 144317
Oral glutamine challenge predicts and identifies long-term ammonia-related overt hepatic encephalopathy
AASLD LiverLearning®, Javier Ampuero, 144318
Genomic Characterization of Stool Microbiota With Rifaximin Monotherapy Versus Lactulose Combination Therapy for Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
AASLD LiverLearning®, Herbert DuPont, 144333
The Impact of Nonselective Beta Blocker on the Liver Stiffness Measurement in Cirrhosis with Severe Portal Hypertension
AASLD LiverLearning®, Yoo Li Lim, 144334
Osteopontin ablation drives hematopoietic stem cell mobilization and increases hepatic iron contributing to alcoholic liver disease
AASLD LiverLearning®, Fernando Magdaleno Verduzco, 144093
Pharmacokinetics (PK), safety and tolerability of the 2- and 3-direct acting antiviral (DAA) combination of AL-335, odalasvir (ODV) and simeprevir (SMV) administered once-daily (QD) in healthy volunteers (HVs)
AASLD LiverLearning®, Thomas Kakuda, 144349
Superior Long-Term Survival following Liver Transplantation in Patients with Alcoholic Liver Disease
AASLD LiverLearning®, George Cholankeril, 144094
Prevalence of Pre-Existing HCV Resistance-Associated Variants and Impact on Treatment Outcome with RG-101 in Combination with Direct Acting Antivirals in HCV Genotype 1 and 4 Infected Patients
AASLD LiverLearning®, Steven Neben, 144350
Hepatic Cell Death Caused by Fungi as well as Bacteria Is Mediated by ROS Induction of Nuclear Transglutaminase in Hepatic Cells
AASLD LiverLearning®, Soichi Kojima, 144109
Intrahepatic Th17/Treg interplay related to fibrosis in Chronic Hepatitis C
AASLD LiverLearning®, Daniela Rios, 144365
Acute Kidney Injury in Alcoholic Hepatitis: Prediction by Tachycardia and Impact on Short-term survival
AASLD LiverLearning®, Sujan Ravi, 144110
Increased duodenal iron absorption through up-regulation of ferroportin 1 due to decrement of serum hepcidin in patients with chronic hepatitis C
AASLD LiverLearning®, Koji Miyanishi, 144366
Immune regulation via the gut-liver axis plays a pivotal role in the pathogenesis of alcohol-induced liver disease
AASLD LiverLearning®, Shunsuke Shiba, 144125
Therapeutic Potential Of Liver X Receptor (LXR) In Alcoholic Liver Disease (ALD)
AASLD LiverLearning®, Monideepa Sengupta, 144126
HCV Infection Induces Caspase Activation and Regulation of Telomerase Expression.
AASLD LiverLearning®, Huy TRAN, 144382
Association of T-Cell Exhaustion Markers, PD-1, TIM-3 and LAG-3 with Liver Cirrhosis, and Responses to Therapy in Chronic HCV-Infected Patients
AASLD LiverLearning®, Enass Abdel-Hameed, 144383